ACTRIMS 2025

Improvements in Health-related Quality of Life and Preserved Cognitive Function in Patients With Relapsing Multiple Sclerosis: 4‑year Results From the CLARIFY-MS Extension Study

Langdon D, et al. 

Durable Effects of Cladribine Tablets on CSF OCB and NfL Over 4 Years in Relapsing Multiple Sclerosis: Results from the MAGNIFY-MS Extension study

Schmierer K, et al.

Durable Impact of Immune Cell Reconstitution Over 4 Years Following Short Course Cladribine Tablets: Results from MAGNIFY-MS Extension Study

Wiendl H, et al.

Pregnancy and Infant Outcomes From an Ongoing Worldwide Enhanced Pharmacovigilance Program of Cladribine Tablets: 7-year Results of MAPLE-MS

Hellwig K, et al.

Safety of Cladribine Tablets in the Treatment of People With Multiple Sclerosis: 2024 Post-Approval Update with a Focus on Infection Risk

Leist T, et al.

CLADRISE Study: Real-World Insights into Cladribine Tablets Treatment Pathways and Their Impact on Relapse Rates in Multiple Sclerosis

Fištravec G, et al.

Real-world Comparative Effectiveness and Persistence of Cladribine Tablets and Other Oral Disease-modifying Treatments for Multiple Sclerosis from GLIMPSE: Results from the MSBase Registry

Butzkueven H, et al.

Immune Cell and Inflammatory Marker Dynamics in Cerebrospinal Fluid After Treatment of Multiple Sclerosis with Cladribine Tablets

Wu G, et al.

Two-Year Findings on the Safety and Efficacy of Cladribine Tablets after Treatment with Natalizumab (CLADRINA Trial)

Sguigna P, et al.

Impact of Cladribine Tablets on Serum Neurofilament Light Chain Levels in Patients with Relapsing Multiple Sclerosis: Results from a US Based Real-world Study

Cote J, et al.